Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.
| Ticker |
SOLV
|
| CIK | 0001964738 |
| SIC | 3841 |
| Sector | Manufacturing |
| Industry Category | Medical Equipment |
| Industry Group | Surgical, Medical, And Dental Instruments And Supplies |
| Address | C/O 3M COMPANY, 3M CENTER, BUILDING 275-6W-02, ST. PAUL, MN, 55144-1000 |
| Website | www.solventum.com/en-us/home/ |
| Phone | 651-733-1110 |
| CEO | Bryan C. Hanson |
| Employees | 22,000 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins ImproveSOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth. Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Solventum (SOLV) Beats Q2 Earnings and Revenue EstimatesSolventum (SOLV) delivered earnings and revenue surprises of +16.55% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Solventum raises annual profit forecast on strength in surgical equipmentMedical device makers have benefited from a surge in demand as more people, particularly older Americans, seek health care services and surgical procedures. Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Solventum: Q2 Earnings SnapshotThe results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.45 per share. The health care company posted revenue of $2.16 billion in the period, also exceeding Street forecasts. |